Author:
Jose Anna Mary,Muntode Pramita
Abstract
A total number of 1,524,161 active cases, 92,941 deaths, and 213 countries have been affected worldwide by COVID-19 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as of 11th April 2020. Much can be attributed to the virus’ structural protein, S protein, which determines its host range and tissue tropism and aids its rapid spread. This review aims to summarize numerous researches carried out with respect to the complex and resistant structure of SARS-CoV-2 in addition to the researches performed on various antivirals on the basis of drug repurposing, to aid in better understanding for future researches, clinical trials, and treatment protocols
Publisher
Jaypee Brothers Medical Publishing
Reference91 articles.
1. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/naming-the-coronavirus-disease-(covid-2019)-andthe-virus-that-causes-it
2. https://www.who.int/emergencies/diseases/novelcoronavirus-2019
3. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200121-sitrep-1-2019-ncov.pdf?sfvrsn=20a99c10_4
4. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30382-2/fulltext
5. Sheahan TP, Sims AC, Leist SR, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun 2020;11(1):222.